This article explores how digital maturity in process design and parameter management can drive significant time and cost savings, streamline tech transfers and ultimately accelerate patient access to ...
We assign Siegfried a Medium Morningstar Uncertainty Rating. Its business is relatively stable, with high switching costs and good visibility due to long-term customer contracts. However, small ...
In January, the U.S. Food and Drug Administration (FDA) issued its first guidance on the use of artificial intelligence (AI) ...
A high drug failure rate is more than just a pattern recognition problem. Here's how we can address some of the root causes.
In addition to supporting NurExone's internal drug development efforts, Exo-Top will be positioned to supply high-quality exosomes to other pharmaceutical ... greater control over its exosome ...
However, as groundbreaking as these therapies are, they also pose unique challenges for the drug development process, particularly regarding quality assurance (QA). The role of QA is more critical ...
On January 6, 2025, the FDA released draft guidance on using artificial intelligence (AI) in regulatory decision-making for ...
South Korea showcases top 10 innovative medical devices at annual report meeting South Korea reveals its top ten groundbreaking healthcare technologies at a major annual event ...
Peethaambaran Kunnathoor, Chennai Saturday, February 8, 2025, 08:00 Hrs [IST] ...
For tech companies, the healthcare vertical is now the fastest growing business. The US, which spends about $5 trillion on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback